Crossmark

Consensus for risk management in the prescription of biologic therapies or targeted synthetic antirheumatic drugs: Colombian Association of Rheumatology 2023

Crossref DOI link: https://doi.org/10.1016/j.rcreue.2024.11.005

Published Print: 2025-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Forero Illera, Elías Gonzalo

Fernández Aldana, Andrés Ricardo

Fernández Ávila, Daniel Gerardo

Jáuregui Cuartas, Edwin Antonio

Vásquez, Gloria

Chalem, Monique

Bautista Molano, Wilson
License Information

Text and Data Mining valid from 2025-01-01

Text and Data Mining valid from 2025-01-01
More Information

This article is maintained by: Elsevier

Article Title: Consensus for risk management in the prescription of biologic therapies or targeted synthetic antirheumatic drugs: Colombian Association of Rheumatology 2023

Journal Title: Revista Colombiana de Reumatología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.rcreue.2024.11.005

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.rcreu.2024.01.007

Content Type: simple-article

Copyright: © 2024 Published by Elsevier España, S.L.U. on behalf of Asociación Colombiana de Reumatología.

Document is current

Any future updates will be listed below